Shares of Oscar Health vaulted 17.7% to $35.45 in pre-market trading on August 7, as investors rushed to position ahead of the company's Q2 2026 earnings report — a move that prices in considerable optimism for a company that has only recently turned the corner toward profitability. Oscar Health Rockets 17.7% After Blowout Q2 — But Has the Stock Already Priced In the Good News?
Shares of Oscar Health surged 17.7% to $35.45 in pre-market trading on August 7, the morning after the insuretech delivered Q2 results that crushed expectations. Oscar posted earnings of $1.10 per diluted share, nearly triple the $0.40 analysts had forecast. The question now: with the stock already up more than 80% this year, how much upside is left?
• A Profit Swing That Changes the Math Entirely. Oscar swung to a profit of $362 million in Q2, compared to a loss of $228.4 million a year ago.
For the first half of 2026, the company generated $1.1 billion in earnings from operations and $1 billion in net income — a record. That kind of turnaround forces analysts to rework their valuation models. A company that was burning cash 12 months ago is now producing it at scale.
• Medical Costs Fell Sharply — the Single Biggest Driver. The Medical Loss Ratio (MLR) — the share of premiums spent paying medical claims — is the number that matters most for health insurers. Oscar's MLR improved 12 percentage points year-over-year to 79.2% in Q2. That means roughly 21 cents of every premium dollar stayed with the company instead of going to hospitals and doctors. Management now expects full-year MLR between 81.5% and 82.5%, an improvement of 90 basis points from prior guidance. If utilization stays favorable, earnings could overshoot even the raised outlook.
• Revenue Surged 70%, But the Company Still Missed Estimates. Oscar brought in $4.9 billion in Q2 revenue, up 70% year-over-year, but missed revenue estimates by 0.92%.
Membership reached 2.96 million, up 46% year-over-year , though it declined from Q1's 3.2 million as government eligibility checks accelerated. Management expects increasing membership losses in the second half as those verification processes ramp up. Revenue growth without member retention would eventually stall.
• Guidance Raised, But the Stock May Already Reflect It. Oscar raised its full-year earnings outlook to $500 million–$700 million, up $250 million from previous guidance.
Revenue guidance was reaffirmed at $18.7 billion–$19 billion. Yet the stock had already climbed from around $27 in June to over $30 before earnings. The core risk is "a stock price that has already capitalized a cleaner claims environment before the full-year risk pool is visible." Investors bidding shares up another 17.7% this morning are betting the profit trajectory will hold through year-end — a bet that leaves little room for a bad quarter.